Elderly patient with complex concomitant cardiovascular disease

Elderly patient with complex concomitant cardiovascular disease

The clinical case we present shows that an inadequate pharmacological treatment of type 2 diabetes does not prevent complications affecting especially the cardiovascular system. Cardiovascular events remain the leading cause of death in people with diabetes. The optimal management of the patient de...

Full description

Bibliographic Details
Main Authors: Vincenzo Cimino, Cristina Albrici, Angela Ida Pincelli, Damiano Calella, Silvia Galliani, Francesca Pesenti, Mario Perotti
Format: Article
Language:English
Published: AboutScience Srl 2018-08-01
Series:AboutOpen
Subjects:
Type 2 diabetes
Cardiovascular risk
Empagliflozin
Online Access:https://journals.aboutscience.eu/index.php/aboutopen/article/view/151
id doaj-086acf3ea99d4cbb872c98d10b1fd513
record_format Article
spelling doaj-086acf3ea99d4cbb872c98d10b1fd5132020-11-25T02:10:41ZengAboutScience SrlAboutOpen2465-26282018-08-014110.19156/abtpn.2018.0051Elderly patient with complex concomitant cardiovascular diseaseVincenzo Cimino0Cristina Albrici1Angela Ida Pincelli2Damiano Calella3Silvia Galliani4Francesca Pesenti5Mario Perotti6Scuola di Specializzazione in Endocrinologia, Università dell’Insubria, UO di Diabetologia, Ospedale San Gerardo di Monza - Monza (MB) - ItalyScuola di Medicina e Chirurgia, Università di Milano Bicocca, Milano - ItalyDiabetologia, Ospedale San Gerardo di Monza, Monza (MB) - ItalyScuola di Specializzazione in Endocrinologia, Università dell’Insubria, UO di Diabetologia, Ospedale San Gerardo di Monza, Monza (MB) - ItalyScuola di Specializzazione in Endocrinologia, Università dell’Insubria, UO di Diabetologia, Ospedale San Gerardo di Monza, Monza (MB) - ItalyScuola di Specializzazione in Endocrinologia, Università dell’Insubria, UO di Diabetologia, Ospedale San Gerardo di Monza, Monza (MB) - ItalyDiabetologia, Ospedale San Gerardo di Monza, Monza (MB) - Italy The clinical case we present shows that an inadequate pharmacological treatment of type 2 diabetes does not prevent complications affecting especially the cardiovascular system. Cardiovascular events remain the leading cause of death in people with diabetes. The optimal management of the patient described required a global reassessment and the introduction of new therapies which were adapted according to diabetes progression with its associated complications (Diabetology). https://journals.aboutscience.eu/index.php/aboutopen/article/view/151Type 2 diabetesCardiovascular riskEmpagliflozin
collection DOAJ
language English
format Article
sources DOAJ
author Vincenzo Cimino
Cristina Albrici
Angela Ida Pincelli
Damiano Calella
Silvia Galliani
Francesca Pesenti
Mario Perotti
spellingShingle Vincenzo Cimino
Cristina Albrici
Angela Ida Pincelli
Damiano Calella
Silvia Galliani
Francesca Pesenti
Mario Perotti
Elderly patient with complex concomitant cardiovascular disease
AboutOpen
Type 2 diabetes
Cardiovascular risk
Empagliflozin
author_facet Vincenzo Cimino
Cristina Albrici
Angela Ida Pincelli
Damiano Calella
Silvia Galliani
Francesca Pesenti
Mario Perotti
author_sort Vincenzo Cimino
title Elderly patient with complex concomitant cardiovascular disease
title_short Elderly patient with complex concomitant cardiovascular disease
title_full Elderly patient with complex concomitant cardiovascular disease
title_fullStr Elderly patient with complex concomitant cardiovascular disease
title_full_unstemmed Elderly patient with complex concomitant cardiovascular disease
title_sort elderly patient with complex concomitant cardiovascular disease
publisher AboutScience Srl
series AboutOpen
issn 2465-2628
publishDate 2018-08-01
description The clinical case we present shows that an inadequate pharmacological treatment of type 2 diabetes does not prevent complications affecting especially the cardiovascular system. Cardiovascular events remain the leading cause of death in people with diabetes. The optimal management of the patient described required a global reassessment and the introduction of new therapies which were adapted according to diabetes progression with its associated complications (Diabetology).
topic Type 2 diabetes
Cardiovascular risk
Empagliflozin
url https://journals.aboutscience.eu/index.php/aboutopen/article/view/151
work_keys_str_mv AT vincenzocimino elderlypatientwithcomplexconcomitantcardiovasculardisease
AT cristinaalbrici elderlypatientwithcomplexconcomitantcardiovasculardisease
AT angelaidapincelli elderlypatientwithcomplexconcomitantcardiovasculardisease
AT damianocalella elderlypatientwithcomplexconcomitantcardiovasculardisease
AT silviagalliani elderlypatientwithcomplexconcomitantcardiovasculardisease
AT francescapesenti elderlypatientwithcomplexconcomitantcardiovasculardisease
AT marioperotti elderlypatientwithcomplexconcomitantcardiovasculardisease
_version_ 1724918204588883968

Similar Items